Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Prior treatment

• Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize Carfilzomib), mannitol, sucrose, histidine (as base and hydrochloride salt) and polysorbate 80 or any of the components of study therapy that are not amenable to premedication with steroids and H2 blockers or would prohibit further treatment with these agents.
• Administration of systemic chemotherapy, biological, immunotherapy or any investigational agent (therapeutic or diagnostic) for multiple myeloma except bisphosphonate therapy. Emergency treatment with dexamethasone is allowed when the cumulative dexamethasone dose is less or equal 160 mg. It is allowed to include patients in the trial after 1 cycle (4 weeks) of any anti-myeloma first-line treatment.
• Active congestive heart failure (NYHA Class III to IV), symptomatic cardiac ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within four months prior study entry.
• Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B sAg and core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed).
• Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to study entry.
• Major surgery within 4 weeks prior to cycle 1 day 1 (kyphoplasty is not considered major surgery); subjects should have been fully recovered from any surgical related toxicities.

Other illness

• Acute active, uncontrolled infection
• Second malignancy within the past 5 years except:
  • adequately treated basal cell or squamous cell skin cancer
  • carcinoma in situ of the cervix
  • prostate cancer Gleason Score ≤ 6 with stable PSA over the past 12 months
  • breast carcinoma in situ with full surgical resection
  • treated medullary or papillary thyroid cancer
• Any other clinically significant medical disease or psychiatric condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent.

Lab values

• Any of the following laboratory abnormalities:
  • Absolute neutrophil count (ANC) \< 1,000/μL, unless related to myeloma
  • Platelet count \< 30,000/ μL (in case of platelets \< 50.000 /µl and ≥ 30.000 /µl myeloma bone marrow infiltration should be ≥ 50%)
  • Corrected serum calcium \> 14 mg/dL (\> 3.5 mmol/L); or free ionized calcium \> 6.5 mg/dL (\> 1.6 mmol/L)
  • Serum GOT/AST or SGPT/ALT \> 3.0 x upper limit of normal (ULN) or serum total bilirubin \> 2.0 mg/dL if not due to hereditary abnormalities as Gilbert's disease or hereditary hemolysis (Note: if the mentioned limits for bilirubin or ASAT/ALAT are exceeded, but there is no significant hepatic dysfunction at investigator's discretion, the study office has to be consulted prior to inclusion)
  • Patients with severe renal impairment (eGFR \< 30 ml/min/1.73 m², MDRD formula or CDK-EPI or Creatinine Clearance \< 30 ml/min)

Other

• Patients with known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow)
• Significant neuropathy (Grades 3 to 4, or Grade 2 with pain according CTC V4.03)
• Female patients who are pregnant or lactating
• Participation in any other clinical trial (with the exclusion of observational, non-interventional studies))

• Subjects must have newly diagnosed, untreated, symptomatic (according to the revised CRAB criteria 2014), documented myeloma and have measurable disease (serum M-protein ≥ 1 g/dL (for IgA ≥ 0.5 g/dL) or urine M-protein ≥ 200 mg/24 hours) or in case of oligosecretory myeloma: involved FLC level ≥ 10 mg/dl, provided sFLC ratio is abnormal or in case of asecretory myeloma: \> 1 focal lesions measurable by MRI
  • Subjects must have high-risk myeloma defined as followed:
  • Presence of one or more of the following cytogenetic abnormalities (determined by FISH):
  • Del(17p) in ≥ 10% of purified cells
  • t(4;14)
  • ≥ 3 copies +1q21
  • t(14;16)
  • ISS Stage II or III (all patients)
  • FISH analysis of external laboratories other than Heidelberg is accepted, a list of laboratories will be filed in the study central.
• Must be ≥ 18 years at the time of signing the informed consent form.
• Must be able to adhere to the study visit schedule and other protocol requirements in the investigators opinion.
• WHO performance status 0-3 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions)
• Females of childbearing potential (FCBP) (1) must agree to refrain from becoming pregnant for 28 days prior to initiation of study drug, while on study drug and for 150 days\* after discontinuation from the study drug by using 2 reliable methods of contraception and must agree to regular pregnancy testing during this timeframe.
  • A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months) 3) has achieved menarche at some point.
• Females must agree to abstain from breastfeeding during study participation and 30 days\* after study drug discontinuation.
• Males must agree to use a latex condom during any sexual contact with FCBP while participating in the study and for 150 days\* following discontinuation from this study, even if he has undergone a successful vasectomy.
• Males must also agree to refrain from donating semen or sperm while on treatment with any study drug and for 150 days\* after discontinuation from this study treatment.
• All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment.
• All subjects must agree not to share medication.
• All participating subjects have to follow the requirements of the Lenalidomide Pregnancy Prevention Plan